<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01189526</url>
  </required_header>
  <id_info>
    <org_study_id>RVOIVRI</org_study_id>
    <secondary_id>BRVOIVRI</secondary_id>
    <nct_id>NCT01189526</nct_id>
  </id_info>
  <brief_title>Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)</brief_title>
  <official_title>A Randomized Trial Comparing Intravitreal Ranibizumab and Macular Laser Photocoagulation for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul Retina Investigator Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul Retina Investigator Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy of intravitreal Ranibizumab in comparison
      with macular laser photocoagulation as treatments for macular edema secondary to branch
      retinal vein occlusion.

      Characteristics of this study is as below

        1. Multicenter, randomized clinical trial. (intravitreal Ranibizumab 0.5mg injection vs.
           macular laser photocoagulation)

        2. After 48 weeks follow up, functional change(visual acuity)and anatomical change (central
           retinal thickness) would be evaluated
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity (ETDRS letters)</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal Thickening</measure>
    <time_frame>48 weeks</time_frame>
    <description>Optical Coherence Tomography measured central retinal thickness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Branch Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>IVRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IVRI : intravitreal ranibizumab (0.5mg) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laser : macular laser photocoagulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Ranibizumab 0.5mg Ranibizumab will be administered to patients as multiple intravitreal injections.</description>
    <arm_group_label>IVRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>macular laser photocoagulation</intervention_name>
    <description>Treatment may include both focal and grid therapy using the laser and contact lens of the investigator's choice.</description>
    <arm_group_label>Laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptom duration &lt; 6 Months, &gt; 4 weeks

          -  Visual acuity - less than 20/40 (73 letters) more than 20/400 (19 letters) in ETDRS
             chart

          -  OCT - center involved retinal thickening : &gt; 250 micrometers

          -  clear media

          -  well controlled hypertension (&lt;140/90mmHg) and diabetes (6.5&lt;HbA1c&lt;9.5)

          -  willing to return for all scheduled visits

        Exclusion Criteria:

          -  uveitis,NVG, exudative AMD, diabetic retinopathy, Irvine-Gass syndrome, OIS

          -  any malignancy

          -  previous treatment history - laser photocoagulation, intravitreal injection with any
             drug, vitrectomy

          -  vitreomacular traction or epiretinal membrane

          -  intraocular surgery in the study eye within 6 months

          -  uncontrolled glaucoma ( &gt; 30mmHg with anti-glaucoma medications)

          -  optic neuropathy, amblyopia

          -  A condition that in the opinion of the investigator would preclude a patient's
             participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Se Woong Kang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae Pil Shin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Kyungpook National University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Song Ee Chung, M.D.</last_name>
    <email>songee129@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yun Taek Kim, M.D.</last_name>
    <email>jjongofhim@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Song Ee Chung, M.D.</last_name>
      <email>songee129@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Song Ee Chung, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yun Taek Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2010</study_first_submitted>
  <study_first_submitted_qc>August 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2010</study_first_posted>
  <last_update_submitted>August 25, 2010</last_update_submitted>
  <last_update_submitted_qc>August 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Se Woong Kan, M.D. and Jae Pil Shin, M.D.</name_title>
    <organization>Samsung Medical Center and Kyungpook National University</organization>
  </responsible_party>
  <keyword>Branch retinal vein occlusion</keyword>
  <keyword>macular edema</keyword>
  <keyword>intravitreal injection</keyword>
  <keyword>ranibizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

